Sight Diagnostics is a technology company.
Sight Diagnostics has raised $124.0M across 5 funding rounds.
Sight Diagnostics has raised $124.0M in total across 5 funding rounds.
Sight Diagnostics is an Israeli medical-device company founded in 2010 that develops AI-driven, image-based blood diagnostic systems for rapid, point-of-care hematology testing.[1] Its flagship product, OLO, performs lab-grade complete blood counts (CBCs) and other tests from a finger-prick capillary blood sample using digital fluorescent microscopy and machine-learning algorithms, delivering results in minutes to serve outpatient clinics, urgent care centers, small hospitals, and resource-limited settings.[1] This addresses the problem of slow, centralized lab testing by enabling decentralized, convenient diagnostics, with the company showing growth through regulatory approvals (e.g., Health Canada), international partnerships, multiple funding rounds, and operations across the U.S., Europe, and Asia.[1]
Sight Diagnostics originated from early work on Parasight, a malaria diagnostic system leveraging the same imaging and AI technology, which was successfully deployed in multiple countries and proved the team's ability to commercialize machine-vision diagnostics for global health challenges.[1] Founded in 2010 in Tel Aviv, the company has evolved from this foundation into a broader hematology platform, expanding via product commercialization, geographic reach, and investor backing from firms like OurCrowd.[1][3] With a workforce of a few hundred employees, pivotal moments include OLO's development as a competitor to traditional lab analyzers and ongoing fundraising for international market entry.[1]
Sight Diagnostics rides the AI-in-healthcare trend, particularly in decentralizing diagnostics amid rising demand for rapid testing post-COVID and in telemedicine growth.[1] Timing aligns with advances in machine vision and edge AI, enabling portable devices that counter centralized lab bottlenecks, especially in underserved regions or high-volume outpatient care.[1] Market forces like aging populations, chronic disease prevalence, and global health initiatives favor it, as does competition from traditional analyzers creating opportunities for disruption.[1] The company influences the ecosystem by validating AI for hematology, paving the way for similar tech in other diagnostics and attracting investment into Israeli medtech.[1][3]
Sight Diagnostics is poised for accelerated growth through OLO commercialization, further regulatory wins (e.g., FDA expansion), and potential IPO amid pre-IPO interest.[1][4] Trends like AI integration in medtech, point-of-care expansion, and immune cell analysis (hinted in recent pivots) will shape its path, potentially evolving into broader immune signature platforms.[2] Its influence may grow by setting standards for AI diagnostics, tying back to its mission of fast, pain-free blood testing that transforms access to critical health insights.[1]
Sight Diagnostics has raised $124.0M in total across 5 funding rounds.
Sight Diagnostics's investors include 360 Capital Partners, Canaan Partners Israel, OurCrowd, Chaim Meir Tessler, kobi marenko.
Sight Diagnostics has raised $124.0M across 5 funding rounds. Most recently, it raised $71.0M Series D in August 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Aug 1, 2020 | $71.0M Series D | 360 Capital Partners, Canaan Partners Israel, OurCrowd, Chaim Meir Tessler, kobi marenko | |
| Feb 1, 2019 | $28.0M Series C | 360 Capital Partners, Canaan Partners Israel, OurCrowd, Chaim Meir Tessler, kobi marenko | |
| Aug 1, 2016 | $16.0M Series B | 360 Capital Partners, Canaan Partners Israel, OurCrowd, Chaim Meir Tessler, kobi marenko | |
| Oct 1, 2014 | $6.0M Series A | 360 Capital Partners, Canaan Partners Israel, OurCrowd, Chaim Meir Tessler, kobi marenko | |
| Jul 1, 2011 | $3.0M Seed | 360 Capital Partners, Canaan Partners Israel, OurCrowd, Chaim Meir Tessler, kobi marenko |